FEDERAL COURT OF AUSTRALIA
Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 2)
[2019] FCA 154
File number: NSD 656 of 2017 Judge: NICHOLAS J Date of judgment: 19 February 2019 Catchwords: PATENTS – application by patentee to amend patent pursuant to s 105(1) of the Patents Act 1990 (Cth) – discretion – relevant considerations – where following grant patentee made amendments to claims of patent applications in other jurisdictions – relevance of such amendments – whether patentee knew or ought reasonably to have known that there was a need for amendments to patent – whether amendments should be refused by reason of patentee’s delay in making application
Held: amendments allowed
Legislation: Patents Act 1990 (Cth) ss 45(3), 102, 105(1) Cases cited: Bayer Pharma Aktiengesellschaft v Generic Health (2012) 99 IPR 59
CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) (2010) 190 FCR 522
Les Laboratories Servier v Apotex (2010) 89 IPR 219
Les Laboratories Servier v Apotex (2016) 247 FCR 61
Smith Kline & French Laboratories Ltd v Evans Medical Ltd [1989] 1 FSR 561
Date of hearing: 12 and 13 November 2018 Registry: New South Wales Division: General Division National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Category: Catchwords Number of paragraphs: 132 Counsel for the Applicant: Mr D Shavin QC with Ms L Thomas Solicitor for the Applicant: DLA Piper Australia Counsel for the First Respondent: Mr A Fox Solicitor for the First Respondent: Dentons Counsel for the Second Respondent: Mr N Murray SC with Ms F St John Solicitor for the Second Respondent: Herbert Smith Freehills ORDERS
NSD 656 of 2017 BETWEEN: NEURIM PHARMACEUTICALS (1991) LTD
Applicant
AND: GENERIC PARTNERS PTY LTD (ACN 132 833 777)
First Respondent
APOTEX PTY LTD (ACN 096 916 148)
Second Respondent
JUDGE:
NICHOLAS J
DATE OF ORDER:
19 FEBRUARY 2019
THE COURT ORDERS THAT:
1.Pursuant to s 105(1) of the Patents Act 1990 (Cth), direct that Australian Patent No 2002326114 be amended in the manner set out in Annexure 1 to the applicant’s “Statement of Grounds in Support of the s 105 Amendments” filed on 1 June 2017.
2.The applicant pay the respondents’ costs of the interlocutory application dated 5 May 2017.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
NICHOLAS J:
BACKGROUND
Before me is an interlocutory application filed 5 May 2017 in a proceeding brought by Neurim Pharmaceuticals (1991) Ltd (“Neruim”) against Generic Partners Pty Ltd (“GPPL”) and Apotex Pty Ltd (“Apotex”) for alleged patent infringement. The patent in suit (“the Patent”) is Australian Patent No 2002326114 entitled “Method for Treating Primary Insomnia” which was based on a PCT application filed on 12 August 2002 (“the PCT application”) and claiming priority from a patent application filed in Israel on 14 August 2001. The Patent was granted on 5 July 2007.
Neurim’s interlocutory application seeks orders pursuant to s 105(1) of the Patents Act 1990 (Cth) (“the Act”) for the amendment…
Keep reading for free
Create a free CaseChat account to read Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2019] FCA 154
- Decision Date
CaseChat Overview and Summary
The central issue was whether Neurim reasonably believed no amendment was necessary and whether the delay in applying for amendment should result in the refusal of the application. The court needed to balance the patentee's right to amend their patent against the public interest in prompt amendment applications. Neurim argued that they reasonably believed no amendment was necessary and moved promptly upon learning of the potential need for amendments.
The court examined the guiding principles for exercising the discretion under s 105 of the Patents Act 1990 (Cth), including the onus on the patentee to establish the need for amendment, the importance of prompt application, and the public interest in preventing unfair advantage. The court found that Neurim reasonably believed no amendment was necessary and acted promptly upon learning of the potential need. The court also considered the scope of the patent claims and the prior art, concluding that Neurim had not sought to obtain an unfair advantage.
The court allowed the amendment application, emphasising the broad discretion under s 105 and the need to balance the patentee's rights with the public interest. The court ordered the patent to be amended as requested and directed that Neurim pay the respondents' costs of the interlocutory application.
Orders
Orders of the court
1. Pursuant to s 105(1) of the Patents Act 1990 (Cth), direct that Australian Patent No 2002326114 be amended in the manner set out in Annexure 1 to the applicant’s “Statement of Grounds in Support of the s 105 Amendments” filed on 1 June 2017.
2. The applicant pay the respondents’ costs of the interlocutory application dated 5 May 2017.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Neurim submitted that at all relevant times it reasonably believed that no amendment was necessary. It was only when Mr Tyacke raised with Professor Zisapel the possibility of making amendments to the Patent that she considered making them. Neurim submitted that from that moment it has moved promptly. CONSIDERATION The discretion arising under s 105 of the Act is broad. However, it is generally exercised by reference to a number of guiding principles that seek to balance the right of the patentee to apply to amend its patent in an appropriate case and the public interest in ensuring that an amendment application is made promptly, for proper purposes, and not so as to allow the patentee to obtain an unfair advantage were it to be allowed. The most well-known statement of the guiding principles appears in the following passage from judgment of Aldous J in Smith Kline & French Laboratories Ltd v Evans Medical Ltd [1989] 1 FSR 561 at 569:The discretion as to whether or not to allow amendment is a wide one and the cases illustrate some principles which are applicable to the present case. First, the onus to establish that amendment should be allowed is upon the patentee and full disclosure must be made of all relevant matters. If there is a failure to disclose all the relevant matters, amendment will be refused. Secondly, amendment will be allowed provided the amendments are permitted under the Act and no circumstances arise which would lead the court to refuse the amendment. Thirdly, it is in the public interest that amendment is sought promptly. Thus, in cases where a patentee delays for an unreasonable period before seeking amendment, it will not be allowed unless the patentee shows reasonable grounds for his delay. Such includes cases where a patentee believed that amendment was not necessary and had reasonable grounds for that belief. Fourthly, a patentee who seeks to obtain an unfair advantage from a patent, which he knows or should have known should be amended, will not be allowed to amend. Such a case is where a patentee threatens an infringer with his unamended patent after he knows or should have known of the need to amend. Fifthly, the court is concerned with the conduct of the patentee and not with the merit of the invention. The fact that a patentee failed to act promptly after becoming aware of facts or circumstances that would lead a reasonable person to apply to amend the claim may provide a sufficient basis for refusing an application to amend. Such facts and circumstances will usually include the state of the prior art and the patentee’s knowledge of it and the scope of the relevant claim including, for example, the absence of any limitation that the patentee may wish to introduce. Ultimately, however, these are matters that must be considered in light of all other facts and circumstances relevant to the exercise of a broad statutory discretion. An assumption underlying Apotex’s submissions is that Neurim understood, or ought reasonably to have understood, that there was a need to amend claim 1 to avoid the relevant prior art. The correctness of that assumption depends upon a consideration of the scope of claim 1 and the relevant prior art.